Intellia Therapeutics Inc (NASDAQ:NTLA)’s share price traded down 1.6% during mid-day trading on Monday . The company traded as low as $17.05 and last traded at $17.42, with a volume of 89,009 shares traded. The stock had previously closed at $17.70.

A number of equities analysts recently issued reports on the stock. Credit Suisse Group AG assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $39.00 price objective for the company. Leerink Swann assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “market perform” rating and a $32.00 price objective for the company. Wedbush assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set an “outperform” rating and a $38.00 price objective for the company. Finally, Jefferies Group assumed coverage on shares of Intellia Therapeutics in a research report on Tuesday, May 31st. They set a “hold” rating and a $33.00 price objective for the company.

The firm’s market capitalization is $636.41 million. The stock’s 50-day moving average is $24.32 and its 200 day moving average is $24.97.

In other Intellia Therapeutics news, Director Carl L. Gordon bought 250,000 shares of the business’s stock in a transaction on Wednesday, May 11th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $4,500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Institutes For Biomed Novartis acquired 277,777 shares of the business’s stock in a transaction dated Wednesday, May 11th. The stock was purchased at an average price of $18.00 per share, with a total value of $4,999,986.00. The disclosure for this purchase can be found here.

Intellia Therapeutics, Inc is a United States-based genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. The Company’s CRISPR/Cas9 technology edits diseased genes in the human body through a single treatment course. It focuses on the therapeutic applications of CRISPR/Cas9 genome editing.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.